The Economic Times
English EditionEnglish Editionहिन्दी
| 03 March, 2021, 09:18 PM IST | E-Paper
Search
+

    After rallying 52% in a month, can Piramal Enterprises sustain its momentum?

    The stock momentum may sustain given the improving prospects of its pharmaceutical division and a possibility of its demerger and listing in the medium term.

    Synopsis

    The company’s management has guided for a 15% organic revenue growth in the pharma business for FY22 compared with the 1% growth in the first nine months of FY21.

    ET Intelligence Group: The stock of Piramal Enterprises has gained nearly 52% since the beginning of February largely on account of developments in its finance business such as the acquisition of DHFL, entry into retail lending, and recovery in the property market. The stock momentum may sustain given the improving prospects of its pharmaceutical division and a possibility of its demerger and listing in the medium term. The company’s management
    Share This Article
    • GIFT ARTICLE
    • FONT SIZE
    • SAVE
    • COMMENT

    Sign in to read the full article

    You’ve got this Prime Story as a Free Gift

    Why ?

    • Sharp Insight-rich, Indepth stories across 20+ sectors

    • Access the exclusive Economic Times stories, Editorial and Expert opinion

    • Clean experience with
      Minimal Ads
    • Comment & Engage with ET Prime community
    • Exclusive invites to Virtual Events with Industry Leaders
    • A trusted team of Journalists & Analysts who can best filter signal from noise
    The Economic Times